新型壳聚糖基自组装纳米胶束紫杉醇药物释放载体

以N-胆甾醇琥珀酰基-O-羧甲基壳聚糖(CCMC, 胆甾醇基取代度6.9%)为原料, 在水溶液中通过探头超声处理制备其自组装凝胶纳米胶束, 采用稳态荧光探针法考察临界胶束浓度, 并通过透射电镜和动态激光散射仪检测胶束的形态大小. 以紫杉醇为模型药物, 采用透析法制备载药CCMC纳米胶束, 并通过高效液相色谱法(HPLC)考察其在纳米胶束中的包载及释放情况. 结果显示, CCMC为两亲性高分子, 在水溶液中能形成粒径为198.4 nm的规则球状胶束, 临界胶束浓度为0.018 mg/mL. 紫杉醇顺利包载于CCMC-纳米胶束内, 载药量高达34.9%; 随着载药量的增加, 胶束粒径呈增大的趋势. 体外释放实验结果显示, CCMC纳米胶束能延缓紫杉醇的释放, 释药速度和释放介质pH值密切相关.     

顺铂温敏载药粒子的制备表征

制备了顺铂温敏载药纳米粒子，表征其相关性质并考察不同温度下对体外肿瘤细胞的生长抑制作用。制备的两亲嵌段聚合物在水溶液中自发形成胶束结构并包裹顺铂，测定顺铂载药粒子的结构、形态、粒径及包封率、载药量、晶体状态等特性，并对顺铂的体外释放以及不同细胞系体外毒性也做了研究。载药粒子粒径为83.3 ± 4.3 nm，载药量为37.8%，包封率为77.8%。血清中相变温度39.3 ℃。载药颗粒在单纯化疗时细胞抑制率较小，加热后抑制作用明显增加(P<0.01)，与游离药物相近(P>0.5)。顺铂载药纳米粒子具有较好的温控特性，为顺铂在肿瘤热靶向治疗中的应用提供了一条新的途径。     

共同装载吴茱萸碱和Fe3O4纳米粒子的磁性药物载体的制备

以单甲醚-聚乙二醇-聚（丙交酯-乙交酯）（mPEG-PLGA）作为载体,采用溶液透析的方法共同装载抗癌药物吴茱萸碱和Fe₃O₄ 磁性纳米粒子. 通过透射电子显微镜、红外光谱、紫外-可见光谱及体外释放实验、普鲁士蓝染色、体外毒性实验和磁靶向研究,综合评价了磁性纳米药物载体的性能. 结果表明,磁性药物载体胶束分散性良好,粒径均一,有较高的载药量和包封率,能够实现药物缓释,具有磁靶向特性.     

高效氯氰菊酯微胶囊的制备、表征及释放性能

以高效氯氰菊酯为芯材, 乙基纤维素为壁材, 采用溶剂蒸发法制备了微胶囊, 并对其理化性能进行表征, 通过单因素实验研究了工艺参数对微胶囊外观形貌、 粒径大小及分布、 包封率、 载药量和缓释性能的影响. 结果表明, 乳化剂种类和剪切时间可以显著影响微胶囊的外观形貌; 随着乳化剂用量增大, 微胶囊粒径减小, 分布变窄, 当Tween-80用量从4%增加至8%时, 微胶囊平均粒径从59.9 μm减少到29.8 μm, 跨距也从1.21减少到0.72. 随着芯壁比(质量比)减小, 微胶囊粒径和包封率均逐渐增大, 载药量逐渐减小, 当芯壁比为1:1.75时, 包封率可以达到70%以上. 微胶囊释放动力学模型符合Ritger-Peppas模型(lgQ=lgk+nlgt); 平均粒径相近而载药量不同时, 初期载药量最小的样品释放速率慢, 累积释放率低; 载药量相近而平均粒径不同时, 粒径大的样品释放速率低, 累积释放率也低.     

羧甲基壳聚糖基胶束的制备及其缓释性

以羧甲基壳聚糖接枝聚己内酯(CMCS-g-PCL)作为阿帕替尼的载体,制备了载药胶束以降低阿帕替尼的副作用。通过紫外-可见分光光度法,分别研究了采用乳化-挥发法、透析法以及薄膜水化法所制得载药胶束的包封率及载药量,并对胶束的稳定性、缓释性以及细胞毒性进行了研究。研究表明:乳化-挥发法最适合用于制备载药胶束,制得的胶束平均粒径在100~150nm,在水溶液中能够稳定维持21d以上,而在PBS溶液中仅能维持7d左右。该载药胶束具有良好的缓释效果,且释放率随着载体接枝率的上升而下降。细胞增殖抑制实验证明,载药胶束对人脐静脉内皮细胞(HUVECs)的抑制效果随着培养时间的推移逐渐增大,有利于实现长效治疗。     

大麻二酚纳米结构脂质载体的制备及其性质研究

通过高压均质法制备包载大麻二酚(CBD)的纳米结构脂质载体(CBD-NLC),并考察其载药量、包封率、平均粒径、Zeta电位、长期储存稳定性等物理化学性质,筛选获得CBD-NLC最佳配方。在优化条件下制备的CBD-NLC平均粒径为163.7±1.3nm,多分散性指数(PDI)为0.14±0.02,包封率和载药量分别为95.5±1.0%和9.8±0.1%。通过透射电镜、傅里叶变换红外光谱、差示量热扫描、X射线衍射对CBD-NLC进行表征,结果表明,CBD被很好地负载在NLC中,CBD-NLC主要为球形结构。与文献报道相比,纳米结构脂质载体能够包载CBD,具有较好的载药量和包封率,可解决CBD的溶解性及稳定性问题,提高CBD的有效利用度。制备的CBD-NLC可用去离子水以任意比例稀释,具有良好的稳定性,便于其在医药产品中的应用。     

壳聚糖基阳离子胶束用于共负载两种不同性质药物的研究

以季胺化壳聚糖-O-聚己内酯(TMC-PCL)胶束为载体,用于共负载2种不同亲疏水性质的抗肿瘤物质,阿霉素和吲哚菁绿;并研究了胶束包埋对吲哚菁绿的稳定性和光热效应的影响,以及阿霉素从胶束中的释放行为.结果表明,2种抗肿瘤物质在TMC-PCL胶束中的实际载药量均可达20％,且包封率超过85％.进一步还用MTT法评价了不同载药胶束体系对肿瘤细胞的杀灭作用,发现共负载胶束经近红外激光辐照后,对肿瘤细胞的毒性远高于单载药体系.     

pH响应性聚合物胶束的制备、表征及对阿霉素的控制释放研究

以主链含腙键的聚乙二醇大分子(PEG-NH-N=CH-OH)为引发剂,通过开环聚合己内酯(ε-CL),制备了一种具有pH响应性的两亲性嵌段共聚物PEG-NH-N=CH-PCL.运用核磁共振(~1H NMR)、透射电镜(TEM)和动态光散射(DLS)等对聚合物的结构、胶束的形貌及粒径进行表征.结果表明,聚合物胶束呈规整球形且分布均匀,平均粒径约98nm,pH 5.0时胶束粒径显著增加.负载阿霉素(DOX)的聚合物胶束的载药量为16.4%,包封率为57.4%.体外释放研究表明,pH 5.0时药物释放速率比pH 7.4时快,48h后累计释放率达91.1%.因此,该pH响应性聚合物胶束作为抗癌药物载体具有潜在的应用价值.     

载紫杉醇星型M-PLA-TPGS纳米颗粒的合成及其用于前列腺癌治疗药物载体的研究

合成了一种甘露醇引发的星型共聚物甘露醇-聚乳酸-聚乙三醇1000维生素E琥珀酸酯(M-PLATPGS).利用纳米沉淀法制备载紫杉醇M-PLA-TPGS纳米颗粒.纳米颗粒近似球形,粒径分布较窄.对载药纳米颗粒进行粒径、表面电荷、载药量、包封率和体外药物释放的表征,结果表明,体外药物释放呈双相释放模型,M-PLA-TPGS纳米颗粒在前列腺癌PC-3细胞中的摄取水平要高于PLGA和PLA-TPGS纳米颗粒.载紫杉醇M-PLA-TPGS纳米颗粒对于前列腺癌细胞的的毒性显著高于载紫杉醇PLA-TPGS纳米颗粒和商业制剂Taxol,证明星型M-PLA-TPGS聚合物作为纳米药物载体优于线性PLGA和PLA-TPGS聚合物.     

装载吲哚美辛肝素类纳米胶束的制备及抗凝作用

肝素(hep)作为一种抗凝剂,在临床医学上广泛应用。 本文以肝素为亲水段、去氧胆酸(DOCA)为疏水段合成了一种肝素类两亲性的聚合物(hep-DOCA,HD),并通过水相自组装方法,制备纳米胶束(HD-IDM),装载具有抗血栓作用的吲哚美辛(IDM),协同实现材料的抗凝血功能。 通过动态光散射、Zeta电势和透射电子显微镜(TEM)等技术手段表征了纳米胶束结构和性能。 当纳米胶束载药量为0.0913 mg/mL时,载药纳米胶束浓度为0.4 g/L,此时细胞存活率为92.81%,溶血率为0.83%,表明载药胶束具有良好的生物相容性。 肝素钠,hep-DOCA和HD-IDM的全血凝血指数分别为86.48%、77.47%和89.53%,全血凝血时间分别为927、837和965 s,血栓凝块实验中产生的血栓质量分别为0.11、0.20和0.07 g,证明载药纳米胶束具有优良的抗凝血效果。     

Development of Poly(ethylene glycol) Based Amphiphilic Copolymers for Controlled Release Delivery of Carbofuran

The formation of micelles in a solvent that is selective for one of the blocks is one of the most important and useful properties of block copolymers. We had synthesized copolymers of polyethylene glycol and various dimethyl esters, which self assemble into nano micellar aggregates in aqueous media. In the present work, we have utilized these nano micelles for the encapsulation of carbofuran, [2,3–dihydro-2,2-dimethylbenzofuran-7-yl methylcarbamate], a systemic insecticide-nematicide, for the development of controlled release formulation.     

两亲性类树枝状聚合物的合成与药物控释

结合阴离子开环聚合方法合成了内壳为聚（乙氧基乙基缩水甘油醚）,外层为聚环氧乙烷的两亲性类树枝状嵌段共聚物PEEGE-G2-b-PEO（OH）12. 使用核磁共振氢谱以及凝胶渗透色谱等表征了中间产物和目标产物. 选择阿霉素作为实验药物,研究了该聚合物的载药和控释行为. 聚合物的载药率和包覆效率分别为13.07%和45.75%,体外释放试验表现为持续性的释放,并受到释放介质pH影响.     

Effect of drug-loading methods on drug load, encapsulation efficiency and release properties of alginate/poly-L-arginine/chitosan ternary complex microcapsules

The drug-loaded alginate/poly-L-arginine/chitosan ternary complex microcapsules were prepared by mixing method, absorption method and the combined method of mixing and absorption, respectively. The effect of drug-loading methods on drug load, the encapsulation efficiency and the release properties of the complex microcapsules were investigated. The results showed that the absorption process is a dominating factor to greatly increase the drug load of Hb into microcapsules. Upon loading Hb into microcapsules by combined method of mixing and absorption, the drug load (19.9%) is up to the maximum value, and the encapsulation efficiency is 93.8%. Moreover, the drug release is a zero-order kinetics process for the ternary complex microcapsules made by mixing. For the complex microcapsules made by absorption, the drug release is a first-order kinetics. However, for the complex microcapsules made by combining the mixing and the absorption, the drug release obeys a first-order kinetics during the first eighteen hours, changing afterwards to a zero-order kinetics process. Effect of drug-loading methods on drug load and encapsulation efficiency of alginate/poly-L-arginine/chitosan ternary complex microcapsules.     

Preparation and characteristics of linoleic acid-grafted chitosan oligosaccharide micelles as a carrier for doxorubicin

The linoleic acid (LA)-grafted chitosan oligosaccharide (CSO) (CSO-LA) was synthesized in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and the effects of molecular weight of CSO and the charged amount of LA on the physicochemical properties of CSO-LA were investigated, such as CMC, graft ratio, size, zeta potential. The results showed that these chitosan derivatives were able to self-assemble and form spherical shape polymeric micelles with the size range of 150.7–213.9 nm and the zeta potential range of 57.9–79.9 mV, depending on molecular weight of CSO and the charged amount of LA. Using doxorubicin (DOX) as a model drug, the DOX-loaded CSO-LA micelles were prepared by dialysis method. The drug encapsulation efficiencies (EE) of DOX-loaded CSO-LA micelles were as high as about 75%. The sizes of DOX-loaded CSO-LA micelles with 20% charged DOX (relating the mass of CSO-LA) were near 200 nm, and the drug loading (DL) capacity could reach up to 15%. The in vitro release studies indicated that the drug release from the DOX-loaded CSO-LA micelles was reduced with increasing the graft ratio of CSO-LA, due to the enhanced hydrophobic interaction between hydrophobic drug and hydrophobic segments of CSO-LA. Moreover, the drug release rate from CSO-LA micelles was faster with the drug loading. These data suggested the possible utilization of the amphiphilic micellar chitosan derivatives as carriers for hydrophobic drugs for improving their delivery and release properties.     

Co-delivery of docetaxel and doxorubicin using biodegradable PEG-PLA micelles for treatment of breast cancer with synergistic anti-tumour effects

Poly(ethylene glycol)-poly(lactic acid) copolymer, prepared by ring opening polymerization, was used as a single platform to co-deliver both hydrophilic doxorubicin and hydrophobic docetaxel (DTX) in a simulated physiological environment. The average size of the negatively charged drug loaded polymeric micelles were found to be 293 nm. The drug loading (%) and encapsulation efficiency (%) were calculated to be 1.21 and 59.0, respectively. The in vitro cytotoxicity test using MCF7 breast cancer cells was conducted using 1 × 10⁴ cells in 10% FBS and 1% antibiotic, and the absorbance of formazan was evaluated at 570 nm. Cell growth inhibition by MTT assay showed viability of 33% of the MCF7 cells after treatment with drug-loaded micelles for 48 h. Controlled release of drugs from the polymeric micelles indicated a burst release effect initially; whereas, 98% of drug could be released at pH 7.4 within a time period of 96 h. Time period for drug release shorten to 48 h only in simulated mild acidic pH (5.4) condition. The in vitro drug release study from micelles indicated synergistic cytotoxicity effect in human metastatic breast cancer MCF7 cell.     

硼酸酯键在药物传递体系中的应用

刺激响应性药物载体由于其优异的控释性能,在生物医药领域引发了广泛的关注并得到了极为快速的发展.硼酸酯键因构筑条件简单、生物相容性好以及能够响应生物体内pH、葡萄糖、三磷酸腺苷(ATP)等多种微环境变化的优势被广泛用于刺激响应性药物载体的构筑.基于硼酸酯键的药物载体类型有药物-聚合物偶联、聚合物胶束、线性-超支化聚合物和介孔二氧化硅等,它们既能负载抗癌药物,又能递送胰岛素和基因.药物通过共价或非共价作用负载到载体上,并利用硼酸酯键在不同环境下的形成与断裂实现药物的可控释放.从药物类型、载体类型、药物与载体的结合方式以及硼酸酯键的断裂机制四个方面综述了硼酸酯键在药物传递体系中的应用,并对其当前面临的主要挑战和未来的发展趋势进行了总结和展望.     

Ultra-High to Ultra-Low Drug-Loaded Micelles: Probing Host–Guest Interactions by Fluorescence Spectroscopy

Polymer micelles are an attractive means to solubilize water insoluble compounds such as drugs. Drug loading, formulations stability and control over drug release are crucial factors for drug-loaded polymer micelles. The interactions between the polymeric host and the guest molecules are considered critical to control these factors but typically barely understood. Here, we compare two isomeric polymer micelles, one of which enables ultra-high curcumin loading exceeding 50 wt.%, while the other allows a drug loading of only 25 wt.%. In the low capacity micelles, steady-state fluorescence revealed a very unusual feature of curcumin fluorescence, a high energy emission at 510 nm. Time-resolved fluorescence upconversion showed that the fluorescence life time of the corresponding species is too short in the high-capacity micelles, preventing an observable emission in steady-state. Therefore, contrary to common perception, stronger interactions between host and guest can be detrimental to the drug loading in polymer micelles.     

Micelles and reverse micelles with a photo and thermo double‐responsive block copolymer

A novel photo and thermo double‐responsive block copolymer was developed to fabricate micelles and reverse micelles in aqueous solution. The block copolymer was synthesized by ATRP block copolymerization of a spiropyran‐ containing methacrylate (SPMA) with di(ethylene glycol) methyl ether methacrylate (DEGMMA). By facile control of the photo irradiation and solution temperature, PSPMA‐core and PDEGMMA‐core micelles can be obtained, respectively. The thermo‐ and photo‐responsive micelles were used as smart polymeric nanocarriers for controlled encapsulation, triggered release, and re‐encapsulation of model drug coumarin 102. The double‐responsive self‐assembly and disassembly were tracked by dynamic light scattering, transmission electron microscopy, and fluorescence spectroscopy. © 2010 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 48: 2855–2861, 2010     

Specific interactions improve the loading capacity of block copolymer micelles in aqueous media

Block copolymer micelles find application in many fields as nanocarriers, especially in drug delivery. We report herein that specific interactions between hydrophobic guest molecules and core-forming segments can significantly improve the loading capacity of polymeric micelles. High loading capacities (>100% weight/weight of polymer (w/wp)) were systematically observed for the encapsulation of probes containing weak carboxylic acid groups by micellar nanoparticles having poly[2-(dialkylamino)ethyl methacrylate] cores (i.e., particles whose cargo space exhibits antagonist weak base functions), as demonstrated by the incorporation of indomethacin (IND), ibuprofen (IBPF), and trans-3,5-bis(trifluoromethyl)cinnamic acid (F-CIN) into either poly(ethylene oxide)-b-poly[2-(diisopropylamino)ethyl methacrylate] (PEO-b-PDPA) or poly(glycerol monomethacrylate)-b-PDPA (PG2MA-b-PDPA) micelles. The esterification of IND yielding to a nonionizable IND ethyl ester derivative (IND-Et) caused an abrupt decrease in the micellar loading capacity down to 10-15% w/wp. Similar results were also obtained when IND was combined with nonionizable block copolymers such as PEO-b-polycaprolactone (PEO-b-PCL) and PEO-b-poly(glycidyl methacrylate) (PEO-b-PGMA). The existence of acid-base interactions between the solubilizate and the weak polybase block forming the micelle core was confirmed by 1H NMR measurements. However, the incorporation of high numbers of hydrophobic guest molecules inside polymeric micelles can provoke not only an increase in the hydrodynamic size (2RH) of the objects but also a substantial change in the morphology (transition from spheres to cylinders). The application of the Higuchi model showed that the probe release followed a diffusion-controlled mechanism, and diffusion coefficients (D) on the order of 10-18-10-17 cm2/s were determined for IND release from 1.0 mg/mL PEO113-b-PDPA50 + 100% w/wp IND. Probe release from micelles with weak polybase-based cores can also be triggered by changes in the solution pH.     

Self‐Assembly Drug Delivery System Based on Programmable Dendritic Peptide Applied in Multidrug Resistance Tumor Therapy

In recent decades, diverse drug delivery systems (DDS) constructed by self‐assembly of dendritic peptides have shown advantages and improvable potential for cancer treatment. Here, an arginine‐enriched dendritic amphiphilic chimeric peptide CRRK(RRCG(Fmoc))₂ containing multiple thiol groups is programmed to form drug‐loaded nano‐micelles by self‐assembly. With a rational design, the branched hydrophobic groups (Fmoc) of the peptides provide a strong hydrophobic force to prevent the drug from premature release, and the reduction‐sensitive disulfide linkages formed between contiguous peptides can control drug release under reducing stimulation. As expected, specific to multidrug resistance (MDR) tumor cells, the arginine‐enriched peptide/drug (PD) nano‐micelles show accurate nuclear localization ability to prevent the drug being pumped by P‐glycoprotein (P‐gp) in vitro, as well as exhibiting satisfactory efficacy for MDR tumor treatment in vivo. This design successfully realizes stimuli‐responsive drug release aimed at MDR tumor cells via an ingenious sequence arrangement.